Memphis-based GTx Inc. marches onward, hoping yet to convince the FDA to approve Acapodene for use in fighting bone fractures in men taking chemo for prostate cancer.
MDN reports. It wasn't so long ago, we note, that Nashville-based BioMimetic had to
shrug-off an FDA bruise, and continues to
move along.
No comments:
Post a Comment